NASDAQ: LEXXLexaria Bioscience Corp Stock Ownership - Who owns Lexaria Bioscience?
Insider buying vs selling
Have Lexaria Bioscience Corp insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Christopher Bunka | Director | 2025-07-30 | 11,900 | $0.91 | $10.86kBuy |
| Christopher Bunka | Director | 2025-07-29 | 15,600 | $0.92 | $14.37kBuy |
| Vanessa Carle | Secretary | 2025-07-29 | 750 | $0.91 | $682.50Buy |
| Richard Christopher | Chief Executive Officer | 2025-07-29 | 15,000 | $0.91 | $13.64kBuy |
| John Martin Docherty | President CSO | 2025-07-29 | 5,376 | $0.93 | $4.99kBuy |
| William Edward McKechnie | Director | 2025-07-29 | 5,000 | $0.91 | $4.53kBuy |
LEXX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when LEXX insiders and whales buy or sell their stock.
LEXX Shareholders
What type of owners hold Lexaria Bioscience Corp stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Christopher Bunka | 2.63% | 655,455 | $458.82k | Insider |
| Invenomic Capital Management LP | 1.89% | 470,915 | $329.64k | Institution |
| Ubs Group Ag | 1.45% | 361,300 | $252.91k | Institution |
| Vanguard Group Inc | 1.04% | 258,816 | $181.17k | Institution |
| Geode Capital Management LLC | 0.88% | 219,718 | $153.80k | Institution |
| Toronto Dominion Bank | 0.56% | 140,013 | $98.01k | Institution |
| Byrne Asset Management LLC | 0.42% | 105,500 | $73.85k | Institution |
| John Martin Docherty | 0.24% | 59,451 | $41.62k | Insider |
| Richard Christopher | 0.20% | 50,000 | $35.00k | Insider |
| State Street Corp | 0.16% | 39,301 | $27.51k | Institution |
LEXX vs Biotech Stocks
Lexaria Bioscience Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.